Research programme - antibody-drug conjugates - Innate Pharma/Sanofi

Drug Profile

Research programme - antibody-drug conjugates - Innate Pharma/Sanofi

Alternative Names: Anticancer therapeutics - Innate Pharma/Sanofi

Latest Information Update: 12 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innate Pharma; Sanofi
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Natural cytotoxicity triggering receptor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 09 Feb 2016 Sanofi and Innate Pharma enter into a research and licensing agreement utlising Innate Pharma’s proprietary technology to develop bispecific antibody conjugates for Cancer
  • 16 Apr 2015 Innate Pharma and Sanofi enter into collaboration to develop antibody-drug conjugates for Cancer
  • 16 Apr 2015 Early research in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top